CPT1A and prostate cancer: Indeed, Schlaepfer et al. showed that the blockage of CPT1A (with etomoxir) and the lipid synthesis/lipolysis (with orlistat) decreased the viability of the androgen-dependent prostate cell lines LNCaP, VCaP, and patient-derived prostate cancer cells34.